Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 1Anxiety Disorders 1

Interventions

Temozolomide 17Bevacizumab 10Radiotherapy 9Carmustine 9Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 7Carboplatin 7Sorafenib 6Lapatinib 6Chemotherapy, Adjuvant 62,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 6temsirolimus 5Vorinostat 5Surgical Procedures, Operative 5Sirolimus 5Radiosurgery 5Radiation 5Dexamethasone 5cediranib 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4Cilengitide 4pazopanib 3Thalidomide 3Procarbazine 3Nivolumab 3Neoadjuvant Therapy 3Irinotecan 3Iodine-125 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Brain Neoplasms × Hormones × Clear all
NCT04301089 2026-03-11

Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
61 enrolled 20 charts
CNS

Anxiety Disorders, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡